Bone and Lymph Node Flare to Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer on 18F-Prostate-Specific Membrane Antigen PET/CT With Decreasing Prostate-Specific Antigen of 0.7 ng/mL

Yang Lu

doi:10.1097/RLU.0000000000004107

Bone and Lymph Node Flare to Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer on ¹⁸F-Prostate-Specific Membrane Antigen PET/CT With Decreasing Prostate-Specific Antigen of 0.7 ng/mL

Yang Lu

Nuclear Medicine

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

A 72-year-old man with prostate cancer was found to have prostate-specific membrane antigen (PSMA)-avid oligometastasis on initial staging with 18F-DCFPyL PET/CT. Meanwhile, his prostate-specific antigen was 10.0 ng/mL, and testosterone level was 381 ng/dL. Six weeks after initiation of treatment on androgen deprivation therapy plus abiraterone, his restaging 18F-DCFPyL PET/CT showed decreased PSMA uptake in primary prostate lesion, but increased uptake in bone and lymph node metastases, whereas his prostate-specific antigen decreased to 0.7 ng/mL, and testosterone level was <3 ng/dL. This case illustrates hormone-sensitive metastatic bone and lymph node flare on 18F-PSMA PET/CT.

Original language	English (US)
Pages (from-to)	664-665
Number of pages	2
Journal	Clinical nuclear medicine
Volume	47
Issue number	7
DOIs	https://doi.org/10.1097/RLU.0000000000004107
State	Published - Jul 1 2022

Keywords

F DCFPyL PET/CT
flare
hormone-sensitive
metastasis
prostate cancer
PSMA

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.1097/RLU.0000000000004107

Fingerprint

Dive into the research topics of 'Bone and Lymph Node Flare to Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer on ¹⁸F-Prostate-Specific Membrane Antigen PET/CT With Decreasing Prostate-Specific Antigen of 0.7 ng/mL'. Together they form a unique fingerprint.

Cite this

@article{81e676cbe1724a69b33607cb6dc9d470,

title = "Bone and Lymph Node Flare to Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer on 18F-Prostate-Specific Membrane Antigen PET/CT With Decreasing Prostate-Specific Antigen of 0.7 ng/mL",

abstract = "A 72-year-old man with prostate cancer was found to have prostate-specific membrane antigen (PSMA)-avid oligometastasis on initial staging with 18F-DCFPyL PET/CT. Meanwhile, his prostate-specific antigen was 10.0 ng/mL, and testosterone level was 381 ng/dL. Six weeks after initiation of treatment on androgen deprivation therapy plus abiraterone, his restaging 18F-DCFPyL PET/CT showed decreased PSMA uptake in primary prostate lesion, but increased uptake in bone and lymph node metastases, whereas his prostate-specific antigen decreased to 0.7 ng/mL, and testosterone level was <3 ng/dL. This case illustrates hormone-sensitive metastatic bone and lymph node flare on 18F-PSMA PET/CT.",

keywords = "F DCFPyL PET/CT, flare, hormone-sensitive, metastasis, prostate cancer, PSMA",

author = "Yang Lu",

year = "2022",

month = jul,

day = "1",

doi = "10.1097/RLU.0000000000004107",

language = "English (US)",

volume = "47",

pages = "664--665",

journal = "Clinical nuclear medicine",

issn = "0363-9762",

publisher = "Lippincott Williams and Wilkins",

number = "7",

}

TY - JOUR

T1 - Bone and Lymph Node Flare to Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer on 18F-Prostate-Specific Membrane Antigen PET/CT With Decreasing Prostate-Specific Antigen of 0.7 ng/mL

AU - Lu, Yang

PY - 2022/7/1

Y1 - 2022/7/1

N2 - A 72-year-old man with prostate cancer was found to have prostate-specific membrane antigen (PSMA)-avid oligometastasis on initial staging with 18F-DCFPyL PET/CT. Meanwhile, his prostate-specific antigen was 10.0 ng/mL, and testosterone level was 381 ng/dL. Six weeks after initiation of treatment on androgen deprivation therapy plus abiraterone, his restaging 18F-DCFPyL PET/CT showed decreased PSMA uptake in primary prostate lesion, but increased uptake in bone and lymph node metastases, whereas his prostate-specific antigen decreased to 0.7 ng/mL, and testosterone level was <3 ng/dL. This case illustrates hormone-sensitive metastatic bone and lymph node flare on 18F-PSMA PET/CT.

AB - A 72-year-old man with prostate cancer was found to have prostate-specific membrane antigen (PSMA)-avid oligometastasis on initial staging with 18F-DCFPyL PET/CT. Meanwhile, his prostate-specific antigen was 10.0 ng/mL, and testosterone level was 381 ng/dL. Six weeks after initiation of treatment on androgen deprivation therapy plus abiraterone, his restaging 18F-DCFPyL PET/CT showed decreased PSMA uptake in primary prostate lesion, but increased uptake in bone and lymph node metastases, whereas his prostate-specific antigen decreased to 0.7 ng/mL, and testosterone level was <3 ng/dL. This case illustrates hormone-sensitive metastatic bone and lymph node flare on 18F-PSMA PET/CT.

KW - F DCFPyL PET/CT

KW - flare

KW - hormone-sensitive

KW - metastasis

KW - prostate cancer

KW - PSMA

UR - http://www.scopus.com/inward/record.url?scp=85131770409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85131770409&partnerID=8YFLogxK

U2 - 10.1097/RLU.0000000000004107

DO - 10.1097/RLU.0000000000004107

M3 - Article

C2 - 35175941

AN - SCOPUS:85131770409

SN - 0363-9762

VL - 47

SP - 664

EP - 665

JO - Clinical nuclear medicine

JF - Clinical nuclear medicine

IS - 7

ER -